In:
Optometry & Contact Lenses, DOZ-Verlag Optische Fachveroffentlichung GmbH, Vol. 3, No. 5 ( 2023-5-30), p. 156-162
Kurzfassung:
Purpose. The aim of this article is to summarise currently approved and future therapy options for age-related macular degeneration (AMD). Further, we discuss how more detailed phenotyping of AMD using multimodal imaging will help identifying novel treatment options in the future. Material and Methods. We carried out a non-systematic literature review between October 1, 2022 and October 15, 2022 using the PubMed database search combinations of “age-related macular degeneration” “anti-VEGF”, “therapy”, “gene therapy” and “multimodal imaging”. Results. The study results demonstrate that lifestyle changes are still pivotal in the prevention of AMD. In the intermediate stages, dietary supplements may be considered and, in the future, systemic medications or laser treatments may show benefits. In the neovascular, exudative end-stage, mono- therapy with anti-VEGF is now supplemented with other treatment options. Finally, regarding geographic atrophy, complement inhibition as a new type of therapy is on the verge of being approved. Conclusion. An exact classification of age-related macular degeneration has brought to light many different therapy options. Even more detailed classification of AMD according to its phenotype using multimodal imaging will hopefully better pinpoint new therapeutic options in the future. Keywords AMD classification, agerelated macular degeneration (AMD), AMD prevention, AMD therapy
Materialart:
Online-Ressource
ISSN:
2748-8217
DOI:
10.54352/dozv.BWQA3644
DOI:
10.54352/dozv.IHYQ1049
Sprache:
Unbekannt
Verlag:
DOZ-Verlag Optische Fachveroffentlichung GmbH
Publikationsdatum:
2023
